The Antidote: Inside the World of New Pharma (80 page)

HCV and,
39
–41,
44
,
49
,
62
–63,
82
,
94
–96,
101
,
106
–7,
148
,
183
,
262
,
356

HIV and,
356
–57

Incivek and,
208
–9,
227
,
229
,
232
,
265
,
289

layoffs and,
89
–90,
94
–96

recruitment of,
39
–42

Launch Week,
277
–83,
293
,
320

Lehman Brothers,
186

Leiden, Jeffrey,
375
,
377
,
386

CF and,
360
–61,
367
–69,
380

HCV and,
360
,
362
,
380

succession and,
357
–59,
361

Lewis, Sinclair,
265

Lewis-Hall, Freda,
183
–84,
200
–201,
207

Lexiva (fosamprenavir, VX-175):

HIV and,
77
,
97
–98,
102
,
111
,
186

Porges on,
97
,
102

Life Sciences Initiative,
156

lifestyle drugs,
46

Eli Lilly and Company,
43
–44,
80
,
316

HCV and,
44
,
48
,
61
–64,
68
,
75
–76,
78
,
82
–83,
105
,
110
,
128
–29,
146
,
227
,
232
,
239

HIV and,
24
,
63
,
82

Vertex’s partnership with,
44
,
48
,
61
–64,
68
,
75
–76,
78
,
82
–83

Lindbergh, Erik,
153
–54

Lipitor,
6
,
98
,
195
,
317

Little, Grady,
96

liver,
5
,
32
,
56
,
105
,
132
,
237
,
255
,
318

HCV and,
42
,
62
–64,
82
,
94
–95,
101
,
129
,
138
–39,
151
,
167
,
194
,
203
,
218
,
256
,
263
,
292
,
373
–74

ICE and,
99
,
215

Liver Meeting,
101
,
209
,
212
,
230
–32,
324
,
343
,
346
–51,
356
–57,
375
–76

Gane’s speech at,
348
–49

Incivek and,
82
–83,
121
,
124
,
149
–50,
155
,
212
,
231
–32,
347
–48

Pharmasset and,
333
,
347
–50

Lovers and Livers
(Duffin),
165

lumacaftor,
see
VX-809

lungs,
67
,
69
,
80
,
119
,
125
–26,
142
–43,
179
–80,
249
,
252
–53,
296
,
302
,
364
,
367
,
382

McCain, John,
176
,
187

McColley, Susanna,
301
–3

McHutchison, John,
207
,
287
–88

departure of,
255
–56

HCV and,
138
–40,
155
,
182
,
357

McKinsey & Company,
115
,
287

McMinn, Rachel,
329
,
331
,
340
–41,
343
–44,
362

Mann-Hester, Kelly Ann,
273
–74,
292
–93

Marion Merrell Dow,
47

market capitalization:

of Merck,
15

of Pharmasset,
346

of Vertex,
185
–86,
247
,
283
,
346
,
357
,
359
,
365
,
372
,
382

see also
stock market

marketing,
3
,
4
,
11
,
55
,
65
,
120
,
150
,
238
,
372

Boger and,
45

CF and,
120

guerrilla,
49
–50

of Incivek,
167
–71,
176
,
185
,
187
,
194
,
200
,
213
–14,
238
,
247
,
264
,
277
,
282
–83,
288
–89,
311
,
332
–33,
341
,
347
,
355
,
378
–79

of Lipitor,
6

by Merck,
98
,
217
,
284

off-label,
46
,
65
,
166
,
195
,
372

Roche-Schering war and,
61
,
165
–66

by Vertex,
26
,
49
–50,
160
,
218
,
240
,
376

markets, market share (for drugs),
4
,
5
,
6
,
12
,
14
,
36
,
141
,
165
,
317

Agenerase (VX-478) and,
46
,
50
,
65
,
98
,
262

AIDS/HIV and,
5
,
36
,
46
,
77
,
183
,
225
–26,
229

CF and,
68
–69,
301
,
326
–27,
343
,
345
,
346
,
353
,
361
–62,
369

in China,
169
–70,
172
–74,
326

disease as opportunity for,
84
,
139

FDA and,
137
–38,
150
,
171
,
238

Incivek (VX-950) and,
93
–94,
100
,
149
,
167
–68,
176
,
187
,
213
–14,
247
,
282
–84,
288
–89,
293
,
324
–25,
327
–28,
340
,
341
–42,
347
–48,
360
,
362
,
363
,
374
,
378

JAK inhibitors and,
177
,
317

Kalydeco (VX-770) and,
343
–46,
353
,
361
–62,
369

Merck and,
19
,
210
,
238
,
287

risk and,
92
–93,
100

timing and,
41

Vertex and,
28
,
45
,
99
–100,
102
,
162
,
171
,
205
,
218
–19,
221
,
238
,
240
,
314
,
315
,
324
–25

Victrelis and,
283
–84,
299
,
307
,
311
,
316
,
342

Vioxx pulled from,
121
–22,
245

VX-740 and,
52

VX-745 and,
71
–72

see also
sales, selling, salespeople

Marks, Andrew,
74
–75,
128

Markush structures,
30
–31,
35

Martinez, Pedro,
96

Meacham, Geoff,
317
–18,
332
,
344

CF and,
297
,
302
,
365

Medicaid,
166
,
305

Medicare,
166
,
203
–4,
208
,
305
,
312

Merck,
1
,
13
–16,
28
,
46
–47,
97
,
101
,
115
,
160
,
163
,
224
,
240
,
244
–47,
276
,
282
,
299
,
321
,
351
,
385

AdComm and,
226
,
230
,
238
,
244
,
264
–68,
272
–73,
275

Boger’s background and,
3
–5,
7
,
15
,
91
,
94
,
132
,
134
,
184
,
381

commercial organization of,
260
–61

comparisons between Vertex and,
88
,
279
,
291
–92

corporate culture of,
161
,
260
–61,
278
,
354

Emmens’s background and,
123
,
210

finances of,
14
–15,
168
,
200
,
245
–47,
265
,
283
–84,
311
,
342

HCV and,
22
,
34
,
44
,
82
,
200
,
207
–8,
216
–18,
223
,
226
–31,
233
,
238
,
244
,
249
,
256
,
260
–61,
263
–64,
284
,
307
,
316
,
347
–49,
357

HIV and,
5
,
14
–15,
19
,
24
–26,
30
–31,
36
,
49
,
94
,
357

honors of,
278
–79

Hurter’s background and,
112
–13

Ken Boger on,
278
–79

Mevacor and,
14
–15

Murcko’s background and,
13
,
15
,
324

NDAs and,
226
–29,
231
,
233
,
238
,
244

and pricing of Victrelis,
283
–84,
286

Roche’s partnership with,
284
,
287
–88

sales and,
277
,
284
–85,
307
,
311

Schering acquired by,
199
–200,
217
–18,
245
,
260
,
311

values and,
162
,
245
–46

Vertex’s partnership with,
107
,
114

Vioxx and,
121
–22,
228
,
238
,
245
,
261
,
279

Washington retroviral conference and,
26
,
30
–31

World War II and,
151
–52

Merck, George,
97
–98,
151
–52,
247
,
279

merimepodib (VX-497),
93
–94,
99
–100,
102
,
105
,
108
,
128

Mevacor,
14
–15

Milestone Day,
320
–24,
327

Millennium Pharmaceuticals,
43
,
55
–56,
84
,
86
,
167

Mitsubishi,
111
,
114
,
169
–70,
326

“Molecular Approaches to Drug Design” (Scolnick),
14
–15

molecular subterfuge,
62

Moore, Jon,
88
–90

J. P. Morgan, JPMorgan Chase & Company,
178
,
297
,
302
,
317
–18,
332
,
344
,
365

J. P. Morgan H&Q Healthcare Conference,
76
–77,
84
,
87
,
101
,
136
,
139
,
153
,
192
–93,
214
–16,
237
–38,
358
,
360
–61,
379
–80

Morgan Stanley,
318
–19,
321

Morningstar,
311

Mueller, Peter,
91
,
126
,
159
,
281
,
370
,
380
,
386

Boger’s relationship with,
163
,
204

CF and,
127
,
180
–81,
201
,
295
,
297
,
382

Condon’s hiring and,
167
–68

earnings calls and,
339
–40

East Asian prospects and,
326
–27

HCV and,
93
,
95
–96,
108
–11,
130
,
161
,
181
,
183
,
299
–300,
347
–49,
356
–58

Incivek and,
109
–11,
168
,
201
–2,
211
,
223
,
227
–29,
232
,
243
–44,
258
,
273
,
276
–77,
285
,
288
–90,
347
,
355